在接受甲维持治疗的患者中,普雷加巴林和甲的血水平:一项观察性研究
Anat Sason1, Miriam Adelson1, Shaul Schreiber1,2,3
1Dr. Miriam and Sheldon G. Adelson Clinic for Drug Abuse, Treatment and Research, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Clinical drug investigation
|June 28, 2025
概括
在甲维持治疗 (MMT) 中滥用普雷加巴林与更高的甲血水平和较差的保留和生存率有关. 监测甲水平对于患者的安全至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 成 药物 药物 药物 药物
- 临床毒理学 临床毒理学
背景情况:
- 普雷加巴林和阿片类药物的组合存在严重的死亡风险.
- 在接受美沙维持治疗 (MMT) 的患者中报告了高比例的滥用普雷加巴林.
- 在MMT患者中,与pregabalin滥用相关的特定风险,特别是关于甲剂量和血度的风险,仍然不清楚.
研究的目的:
- 为了研究在MMT患者中滥用普雷加巴林与甲剂量和血水平之间的关系.
- 评估pregabalin滥用对MMT计划中的保留和生存率的影响.
主要方法:
- 一项观察性研究涉及以色列特拉维夫的273名MMT患者.
- 纳入标准要求与甲血水平评估同时对普雷加巴林进行尿液药物查.
- 从医疗记录中收集了甲剂量,血水平,尿液药物查和患者人口统计数据.
主要成果:
- 与非滥用者相比,滥用普雷加巴林 (阳性尿液查) 的患者表现出明显更高的甲血水平 (693.8vs572.3ng/ml).
- 滥用普雷加巴林与其他物质检测阳性的可能性增加有关,包括二,甲基,和芬太尼.
- 呈阳性普雷加巴林查的患者在MMT中保持和存活率明显较短.
结论:
- 滥用普雷加巴林的MMT患者表现出血甲水平升高,尽管他们接受了正常或低剂量的甲.
- 这些发现强调了在MMT患者中常规监测甲血水平的必要性,以减轻与滥用普雷加巴林相关的风险.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
286
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
286
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
309
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
309
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
459
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
459
Drug Distribution: Plasma Protein Binding
6.8K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
6.8K
Drug Concentrations: Measurements
617
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
617
Drug Concentration Versus Time Correlation
1.2K
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
1.2K


